Fate Therapeutics, Inc.

NASDAQ•FATE

CEO: Dr. Bahram Valamehr M.B.A., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2013-10-01

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Contact Information

12278 Scripps Summit Drive, San Diego, CA, 92131, United States

858-875-1800

www.fatetherapeutics.com

Market Cap

$136.03M

P/E (TTM)

-1.0

17.9

Dividend Yield

52W High

$1.94

52W Low

$0.66

52W Range

40%

Rank62Top 92.6%

1.9

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 1.9 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$1.37M+0.00%

4-Quarter Trend

EPS

-$0.27+0.00%

4-Quarter Trend

FCF

-$24.51M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Significantly Reduced Net loss narrowed to $(136.3) M in 2025 from $(186.3) M in 2024; R&D expenses decreased $27.2 M.

Collaboration Revenue Decline Collaboration revenue dropped $7.0 M to $6.6 M in 2025, reflecting milestone achievement timing in prior year.

FT819 Autoimmunity Pipeline Advances FT819 received RMAT designation; Phase 1 trial ongoing for SLE, showing deep B-cell depletion data.

Cash Position Strengthened Cash, equivalents, and restricted cash totaled $56.9 M as of December 31, 2025, up from $46.3 M.

Risk Factors

Substantial Funding Required Operations require substantial additional funding; failure to secure capital risks delaying development or commercialization efforts.

Complex Manufacturing Hurdles iPSC-derived cell therapy manufacturing is complex, subject to scale-up issues, quality control, and supply chain risks.

Stock Price Volatility Risk Stock price subject to fluctuation; principal stockholders own 40.1% and may exert significant control over company.

Regulatory Approval Uncertainty Novel product candidates face uncertain regulatory approval pathways, potentially requiring costly additional clinical studies.

Outlook

Advance Autoimmune Disease Trials Plan to continue FT819 multi-center Phase 1 trial expansion across SLE, SSc, AAV, and IIM indications.

Progress Solid Tumor Candidates Continue advancing FT825 (HER2) and FT836 (MICA/MICB) Phase 1 trials for advanced solid tumors.

Complete IND-Enabling Activities Completing IND-enabling activities for FT839 in 2026 to support initial clinical investigation for dual-CAR therapy.

Seek Strategic Partnerships Focus on forming new partnerships for research, development, and commercialization of iPSC-derived cell therapies.

Peer Comparison

Revenue (TTM)

IPHA

$36.93M

-61.2%

ALEC

$21.05M

-79.1%

TNXP

$13.11M

+29.8%

Gross Margin (Latest Quarter)

APLT

100.0%

+0.0pp

TNXP

80.4%

+13.6pp

ALEC

63.8%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
PEPG	$368.04M	-4.1	-75.7%	9.8%
FBRX	$334.97M	-9.2	-75.6%	0.0%
ALEC	$242.80M	-1.6	-225.0%	12.4%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-5.6%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026

EPS:-$0.28

Revenue:$1.22M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data